Navigation Links
BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
Date:10/24/2008

t our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (File No. 333-145638), Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.

BCRXW


'/>"/>
SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Calif. , July 29, 2014 Human ... and therapeutic company focused on extending the healthy, high ... Franz Och , Ph.D., an expert in machine ... Scientist. Och comes to HLI from Google where he ... Translate. He will report directly to HLI Co-Founder and ...
(Date:7/29/2014)... (July 29, 2014) Tough, ultralight foam of ... shape through a chemical process invented at Rice University. ... looks like a nanoscale building, with floors and walls ... pair of two-dimensional materials: floors and walls of graphene ... nitride platelets. , The researchers say the foam ...
(Date:7/29/2014)... CITY, Md. , July 29, 2014 /PRNewswire/ ... announced a new and updated program for the ... 10 – 12, 2014 in Amelia Island ... CROs, sites and investigators remains unchanged, however, the ... purposeful exchange and networking opportunity among all stakeholders ...
(Date:7/29/2014)... 2014 Second generation biofuels are a viable ... fuels. However, as natural gas is very cheap, this is ... not as valuable as they could be in comparison to ... projects, has made it difficult for renewable energy developers to ... the ground. For these reasons, certain companies have shifted their ...
Breaking Biology Technology:Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3Tough foam from tiny sheets 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2
... 5 Celator Pharmaceuticals today,announced that Andrew Janoff, ... the company,s business operations and clinical development,programs at ... Investor Conference on Tuesday, February 12, 2008 at ... About Celator, Celator Pharmaceuticals, Inc., is ...
... RICHMOND, Va., Feb. 5 Insmed Inc. (Nasdaq:,INSM) CEO ... House FY09 Budget and Food and Drug Administration statements ... is very pleased to see that the White House ... to,deliver safe and more affordable medicines to Americans., ...
... BioSeek, Inc. today,announced that Roy A. Whitfield has ... directors. Mr. Whitfield had joined BioSeek,s board of,directors ... Company since November,2005., "Roy,s management experience and ... extraordinarily valuable to BioSeek thus,far. We look forward ...
Cached Biology Technology:Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics 2BioSeek Elects Roy Whitfield Executive Chairman of Board of Directors 2
(Date:7/28/2014)... additional coral communities showing signs of damage from the Deepwater ... spill in the Gulf of Mexico. The discovery was made ... at Penn State University. A paper describing this work and ... of Mexico will be published during the last week of ... Proceedings of the National Academy of Sciences . , ...
(Date:7/28/2014)... Essigmann and colleagues from the University of Washington had a ... could induce the virus to mutate uncontrollably, they could force ... that our immune system uses against many viruses. , ... mutate at an enhanced rate, as expected. But it did ... trial reported in 2011. In a new study, however, Essigmann ...
(Date:7/28/2014)... Alzheimer,s disease and other forms of dementia, but the ... , University of Washington bioengineers have a designed a ... the body,s normal proteins into a state that,s linked ... Type 2 diabetes and Lou Gehrig,s disease. The synthetic ... normal state into an abnormally folded form by targeting ...
Breaking Biology News(10 mins):Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3
... State University scientists and practitioners is riding herd on ... billion cattle industry: Bovine Respiratory Disease. BRD is ... United States, accounting for approximately 75 percent of feedlot ... feedlot deaths. BRD causes between $800 million to $900 ...
... (March 5, 2010) Research presented by P&G Beauty ... the American Academy of Dermatology (Miami Beach, FL, March ... insights into how ingredient formulations, care regimens and gene ... discussing a wide range of topics, including lipid metabolism ...
... (March 4, 2010) -- In a leap toward making stem ... Institute at Weill Cornell Medical College have discovered that endothelial ... produce growth factors that can grow copious amounts of adult ... Until now, adult stem cell cultures would die within four ...
Cached Biology News:Bovine respiratory disease 2P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 2P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 3P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 4Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 2Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 3Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 4Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 5Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 6
... is ideal for the ... (1D electrophoresis, 2D electrophoresis, ... Pharmacokinetics & Toxicology (whole ... chromatography); Physical and Material ...
This kit is designed to select cells labeled with fluorescein isothiocyanate- (FITC-) conjugated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
Fujifilm BAS-1800II provides the ideal configuration for a low-cost imager that requires only a small amount of space in the laboratory. The small imager for accurate high-throughput screening...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human HLA-DR TAC is designed to deplete human HLA-DR from samples to isolate resting CD4+ or CD8+ T cells....
Biology Products: